MARCH8 Antibody Summary
| Immunogen |
Antibody was raised against a 17 amino acid synthetic peptide from near the carboxy terminus of human MARCH8. The immunogen is located within the last 50 amino acids of MARCH8.
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
MARCH8
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
PBS
|
| Preservative |
0.02% Sodium Azide
|
| Concentration |
1 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for MARCH8 Antibody
- Cellular modulator of immune recognition
- c-MIR
- EC 6.3.2
- EC 6.3.2.-
- MARCH8
- MARCH-VIII
- MARCH-VIIIcellular modulator of immune recognition
- membrane-associated ring finger (C3HC4) 8
- Membrane-associated RING finger protein 8
- Membrane-associated RING-CH protein VIII
- MIR
- RING finger protein 178
- RNF178
Background
MARCH8 (c-MIR) is a novel E3 ubiquitin ligase designated as the modulator of immune recognition (MIR) family, whose catalytic domain is a variant RING domain (RING-CH domain). MARCH8 was found as a functional and structural homolog of KSHV MIR1 and MIR2. MARCH8 targets B7-2 to lysosomal degradation and down-regulates the B7-2 surface expression through ubiquitination of its cytoplasmic tail. Furthermore, MARCH8 has been shown to down-regulate the expression of transferrin receptor and Fas, an important molecule for the induction of apoptosis. MARCH8 is the first example of an E3 ubiquitin ligase that is capable of inhibiting MHC II expression. Recent findings suggest that MARCH8 may regulate immune responses by promoting ubiquitination of MHC-II and CD86, leading to their subsequent endocytosis and lysosomal degradation.